Acadia Pharma Announces License Agreement With Saniona For SAN711

ACADIA Pharmaceuticals

16.71 CHF 27.68%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that it has reached an exclusive worldwide license agreement with Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-a3 positive allosteric modulator.

The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body.

Acadia said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026.

As per the terms of the License deal, Saniona will receive US$28 million upfront plus potential milestone payments of up to US $582 million. In addition, Saniona is eligible to receive tiered royalties of mid-single digits to low double digits on net sales of commercial products that may result from development of SAN711. The potential milestone payments to Saniona consist of up to US$147 million subject to achievement of development and commercial milestones related to potential first and second indications, and up to US $435 million subject to achievement of thresholds of annual net sales of SAN711 worldwide.

Acadia will lead further clinical development, regulatory submissions, and global commercialization efforts for SAN711 while also providing financial support for Saniona's ongoing Phase 1 study and preparations for Phase 2.